Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
8.49
+0.13 (1.56%)
Nov 21, 2024, 11:14 AM EST - Market open
Company Description
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1ᵦ/NLRP3 driven inflammatory diseases.
It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 24, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 133 |
| CEO | Markus Warmuth |
Contact Details
Address: 321 Harrison Avenue, Suite 900 Boston, Massachusetts 02118 United States | |
| Phone | 617 949 2643 |
| Website | monterosatx.com |
Stock Details
| Ticker Symbol | GLUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001826457 |
| CUSIP Number | 61225M102 |
| ISIN Number | US61225M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Markus Warmuth M.D. | President, Chief Executive Officer and Director |
| Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Jennifer Champoux | Chief Operating Officer |
| Dr. John C. Castle Ph.D. | Chief Data and Information Officer |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer |
| Andrew Funderburk | Senior Vice President and Head of IR and Strategic Finance |
| Philip Nickson J.D., Ph.D. | Chief Business and Legal Officer |
| Magnus Walter DPHIL | Senior Vice President of Drug Discovery |
| Edmund Dunn | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 28, 2024 | 144 | Filing |
| Oct 28, 2024 | 8-K | Current Report |
| Sep 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |